Matthew Barcus
Stock Analyst at Chardan Capital
(3.58)
# 955
Out of 4,415 analysts
22
Total ratings
21.74%
Success rate
18.11%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $45 → $27 | $4.68 | +476.92% | 4 | Jun 22, 2023 | |
| ZURA Zura Bio | Initiates: Buy | $14 | $4.36 | +221.10% | 1 | Jun 14, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $1.05 | +566.67% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $28.78 | +11.19% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $11 | $0.54 | +1,933.27% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.97 | +203.03% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $14.97 | -46.56% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.93 | +222.58% | 3 | Nov 17, 2022 |
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $4.68
Upside: +476.92%
Zura Bio
Jun 14, 2023
Initiates: Buy
Price Target: $14
Current: $4.36
Upside: +221.10%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $1.05
Upside: +566.67%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $28.78
Upside: +11.19%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $11
Current: $0.54
Upside: +1,933.27%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.97
Upside: +203.03%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $14.97
Upside: -46.56%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.93
Upside: +222.58%